Patient positioning systems are devices that are used to situate or immobilize patients during procedures such as surgery and imaging to obtain better images. Its primary function is to protect the physical health and safety of patients before, during, and after the procedure. The main patient positioning systems product types are tables, surgical tables, radiolucent imaging tables, examination tables, and others. A table is a piece of flat-top furniture designed to help medical practitioners place patients correctly without having to lift or exert much effort to provide precise placement for scans, surgeries, and other procedures. These are applied to surgery, diagnostics, and others, which are used by hospitals, ambulatory surgery centers, diagnostic laboratories, and others. The global patient positioning systems market is segmented - 1) By Product: Tables, Surgical Tables, Radiolucent Imaging Tables, Examination Tables, Other Products 2) By Application: Surgery, Diagnostics, Other Application 3) By End User: Hospitals, Ambulatory Surgery Centers, Diagnostic Laboratories, Other End Users The global patient positioning systems market size is expected to grow from $1.24 billion in 2022 to $1.30 billion in 2023 at a compound annual growth rate (CAGR) of 5.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global patient positioning systems market size is expected to reach $1.58 billion in 2027 at a CAGR of 4.9%. Growth in the number of surgeries is expected to propel the growth of the patient positioning systems market going forward. Surgery refers to an invasive procedure where tissues are cut or destroyed to structurally alter or repair the human body. Patient positioning systems are used in a variety of surgeries, including orthopedics, cardiology, and others, to ensure that the patient is in the best possible position for the procedure. For instance, according to the American Joint Replacement Registry's 2022 Annual Report, released on November 2022, hip and knee arthroplasty cases in the US reached around 2.8 million in 2022, an increase of 14% from 2021. Therefore, growth in the number of surgeries drives the growth of the patient positioning systems market. Major players in the patient positioning systems market are Medtronic Plc, Hill-Rom Holdings Inc., Stryker Corporation, Steris Corporation, Span America, Skytron LLC, C-Rad, Leoni AG, Elekta, OPT SurgiSystems S R L, Getinge AB, Mizuho OSI, GF Health Products Inc., Merivaara Corp., Orfit Industries, and Medline Industries Inc. Robotic patient positioning systems are a key trend gaining popularity in the patient positioning systems market. Major companies in the patient positioning systems sector are focused on developing robotic patient positioning systems to decrease the burden and improve patient outcomes. For instance, in 2021, Brainlab, a German-based medical device company, launched Loop-X, a mobile imaging robot. It is uniquely designed with flexible patient positioning and non-isocentric imaging, which helps to reduce the amount of radiation and increases its use in various indications. This mobile imaging robot can be operated remotely using a touchscreen tablet. Loop-X was developed in close collaboration between Brainlab and partner medPhoton located in Salzburg, Austria. In December 2021, Baxter International Inc., a USA-based healthcare company offering various healthcare products, acquired Hill-Rom Holdings, Inc. for $10.5 billion. Through this acquisition, Baxter plans to use its commercial and service infrastructure to extend Hillrom's products into new international markets. It also intends to accelerate its innovation in new areas to boost workflow efficiencies and enhance patient outcomes. Hill-Rom Holdings, Inc. is a USA medtech company offering patient positioning systems. North America was the largest region in the patient positioning systems market in 2022. The regions covered in the global patient positioning system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the patient positioning system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The patient positioning system market consists of the sale of pediatric immobilizers, scancoat, chest and hip positioners. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The patient positioning systems market research report is one of a series of new reports from The Business Research Company that provides patient positioning systems market statistics, including patient positioning systems industry global market size, regional shares, competitors with a patient positioning systems market share, detailed patient positioning systems market segments, market trends and opportunities, and any further data you may need to thrive in the patient positioning systems industry. This patient positioning systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatology endoscopy devices refer to non-invasive devices enabled with a light source and a magnifying lens for improved visualization of the skin's underlying layers. They are primarily used in the detection of skin disorders, structures, patterns, and lesions. The main types of dermatology endoscopy devices are traditional or analog dermatoscopy and digital dermatoscopy. Analog dermatoscopy is also known as chemiluminescence microscopy (ELM) which uses an analog dermatoscopy with magnifying lenses for detailed examination of skin lesions and these are employed in conjunction with a digital camera or smartphone to capture images for subsequent analysis. The major product category is polarized, non-polarized, and hybrid which uses various light sources such as LED, halogen, xenon, and UV and has different modality such as handheld, headband, and trolley-mounted that are used in various applications such as skin cancer, warts, scabies, and other applications. The global dermatology endoscopy devices market is segmented - 1) By Type: Traditional Or Analogue Dermatoscopes, Digital Dermatoscopes 2) By Product: Polarized, Non-Polarized, Hybrid 3) By Light Source: LED (Light Emitting Diode), Halogen, Xenon, UV (Ultraviolet) 4) By Modality: Handheld, Headband, Trolley-Mounted 5) By Application: Skin Cancer, Warts, Scabies, Other Applications The global dermatology endoscopy devices market size is expected to grow from $1.97 billion in 2022 to $2.13 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global dermatology endoscopy devices market size is expected to reach $2.87 billion in 2027 at a CAGR of 7.7%. The rise in the incidence of skin diseases is expected to propel the growth of the dermatology endoscopy devices market going forward. Skin diseases refer to various problems affecting the skin, including infections caused by bacteria, viruses, fungi, allergens, parasites, skin cancer, and other skin diseases. Dermatology endoscopy devices are used for the inspection of skin conditions such as assessing pigmented skin lesions, non-pigmented skin lesions, scabies splinters, psoriasis or eczema, and others to offer effective treatment for skin diseases. For instance, in February 2023, according to the National Psoriasis Foundation, a US-based non-profit organization serving people with psoriasis and psoriatic arthritis, psoriasis affects more than 3% of the adult population in the United States equates to more than 7.5 million people. Therefore, the rise in the incidence of skin diseases drives the growth of the dermatology endoscopy devices market. Major players in the dermatology endoscopy devices market are AMD Global Telemedicine Inc., Bausch Health Companies Inc., Caliber I.D. - Imaging & Diagnostics Inc., Canfield Scientific Inc., DermLite LLC, DermoScan GmbH, Firefly Global, HEINE Optotechnik GmbH and Co. KG, Illuco Corporation Ltd., JEDMED, MetaOptima Technology Inc., Optilia Instruments AB, Pixience Healthcare Technology Solutions, Rudolf Riester GmbH, ALMA LASERS Ltd., Pro Scope Systems, MeKo Laser Material Processing, Biolitec AG, Genesis Biosystems Inc., and Cynosure. Technological advancements are a key trend gaining popularity in the dermatology endoscopy devices market. Major companies in the dermatology endoscopy devices sector are focused on innovating their products to improve the observation power and sustain their position in the market. For instance, in June 2022, Derma Sensor Inc, a US-based health technology company, introduced Derma Sensor, a skin cancer detection device for primary care. The device uses a type of optical technology called Elastic Scattering Spectroscopy (ESS) to take non-invasive samples of tissue, recording cellular-level information from the skin lesion using hundreds of wavelengths of light, comparable to sonar. The Derma Sensor platform gives output directly to the user, eliminating the need for a laboratory or another physician to interpret the spectral data, as the patented algorithm rapidly assesses the data and provides a result in seconds. In April 2022, EMZ Partners, a Germany-based investment firm acquired a majority stake in FotoFinder Systems GmbH for an undisclosed amount. With this partnership, FotoFinder Systems GmbH plans to expand its product offering and reach new markets. FotoFinder Systems GmbH is a Germany-based company that provides skin visualization equipment such as video dermoscopy to dermatologists, dermatology clinics, hospitals, screening facilities, and research organizations. North America was the largest region in the dermatology endoscopy devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global dermatology endoscopy devices market report during the forecast period. The regions covered in the global dermatology endoscopy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology endoscopy devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermatology endoscopy devices market consists of sales of epiluminescence microscopy, digital epiluminescence microscopy, and USB video-dermatoscopy devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatology endoscopy devices market research report is one of a series of new reports from The Business Research Company that provides dermatology endoscopy devices market statistics, including dermatology endoscopy devices industry global market size, regional shares, competitors with a dermatology endoscopy devices market share, detailed dermatology endoscopy devices market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatology endoscopy devices industry. This dermatology endoscopy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Newborn eye imaging systems refers to medical systems that aid to detect congenital ocular defects as soon as possible after birth of babies and help prevent long-term vision loss in a variety of disorders. The new-born eye imaging systems are used for various tests such as the external eye examination, red reflex test, and fundus imaging using a wide-field digital retinal imaging system by an experienced ophthalmologist. The new-born eye imaging systems are used in detecting disease types such as retinopathy of prematurity (ROP), retinal disease, strabismus, refractive error, color blindness, and other diseases and include devices such as basic device, and wireless device. Retinopathy of prematurity (ROP) refers to an eye illness caused by aberrant blood vessel growth in the retina, the light-sensitive nerve tissue that lines the inner back wall of the eye, that happens in babies who are premature (born early) or who weigh less than 3 pounds at birth. The systems are used by hospitals, ophthalmology diagnosis centers, ambulatory surgical centers, and others. The global newborn eye imaging systems market is segmented - 1) By Disease Type: Retinopathy Of Prematurity (ROP), Retinal Disease, Strabismus, Refractive Error, Color Blindness, Other Disease Types 2) By Device Type: Basic Device, Wireless Device 3) By End User: Hospitals, Ophthalmology Diagnosis Centers, Ambulatory Surgical Centers, Other End Users The global newborn eye imaging systems market size is expected to grow from $1.86 billion in 2022 to $1.99 billion in 2023 at a compound annual growth rate (CAGR) of 7.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global newborn eye imaging systems market size is expected to reach $2.58 billion in 2027 at a CAGR of 6.7%. The rapidly rising numbers of babies that are suffering from eye problems are expected to propel the growth of the newborn eye imaging systems market going forward. Eye problems refer to any type of vision loss such as total blindness and partial vision loss or people suffering from some common eye-related defects. Eye impairments in newborns can be congenital (often genetic abnormalities or caused by intrauterine injury) or acquired postnatally. Mothers suffering from diabetes may be one of the reasons for ocular abnormalities in children, along with cocaine linked to both superficial and deep hemorrhages and vascular disruption in the newborn retina. This creates demand for diagnosis and treatment of eye diseases in newborns, driving demand for newborn eye imaging systems. For instance, in April 2022, according to the International Agency for the Prevention of Blindness (IAPB), a US-based international alliance working to promote eye health, 448 million children and teenagers representing ages 0 to 19 were suffering from refractive errors. This includes 109.3 million people with vision-impairing hyperopia and 339.4 million people with myopia of less than 0.75D (diopters) in 2020. 90 million children and teenagers had some degree of vision impairment, of which 2 million were blind, 30 million had moderate-to-severe impairment, and 58 million had mild impairment. Therefore, the rapidly rising numbers of babies that are suffering from eye problems are driving the growth of the newborn eye imaging systems market. Major players in the newborn eye imaging systems market are D-EYE SRL, International Business Machines Corporation (IBM), Servicom Medical (Singapore) Pte. Ltd., Imagine Eyes, Visunex Medical Systems, Remidio Innovative Solutions Pvt. Ltd., Allied Vision Technologies GmbH, Leica Microsystems GmbH, Canon Medical Systems Corporation, Intelligent Retinal Imaging Systems, Carl Zeiss Meditec AG, Nikon Corporation, Kowa American Corporation, Topcon Europe Medical B.V., Next Sight, Veatch Ophthalmic Instruments, Boston Micromachines Corporation, Thales Group, Eye Photo Systems Inc., and Merge Healthcare Inc. Technological advancements are a key trend gaining popularity in the newborn eye imaging systems market. Major companies operating in the newborn eye imaging systems market are focusing on developing technologically advanced systems to sustain their position in the market. For instance, in December 2022, NeoLight Newborn Care, a US-based medical device company for newborns, announced the availability of retinopathy of prematurity progression (ROP) Check, a software utilized in digital care coordination for pediatric retinal screening to identify and track retinopathy of prematurity progression (ROP). The ROP Check system makes sure that all eligible infants in the neonatal intensive care unit (NICU) receive eye exams at the appropriate time and in accordance with predetermined standards and share the same examinations and schedule across both inpatient and outpatient practices. ROP Check has the unique and seamless capability to cross-functionally manage patients or parents, NICUs, NICU ROP coordinators, in house or visiting ophthalmology specialists, billing specialists, discharge leaders and post discharge out-patient physicians. In July 2022, ArchiMed, a France-based investment firm acquired Natus Medical for $1.2 billion. The acquisition helps Natus bring advancements in the standard of care and enhance outcomes and quality of life for patients affected by disorders of the brain, neural pathways, and eight sensory nervous systems as a part of ArchiMed. Natus Medical is a US-based firm offering solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems including newborn eye imaging systems. North America was the largest region in the newborn eye imaging systems market in 2022. The regions covered in the global newborn eye imaging systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the newborn eye imaging systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The newborn eye imaging systems market consists of sales of scanning laser polarimetry (SLP), confocal scanning laser ophthalmoscopes (CSLO), optical coherence tomography (OCT) devices, and pediatric digital retinal imaging systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The newborn eye imaging systems market research report is one of a series of new reports from The Business Research Company that provides newborn eye imaging systems market statistics, including newborn eye imaging systems industry global market size, regional shares, competitors with newborn eye imaging systems market share, detailed newborn eye imaging systems market segments, market trends, and opportunities, and any further data you may need to thrive in the newborn eye imaging systems industry. This newborn eye imaging systems market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Gynecological devices are instruments designed for the management of the female’s reproductive system, childbirth, and pregnancy. Gynecology devices are used to perform various medical procedures for the well-being of females. The main types of gynecological devices are surgical devices, diagnostic imaging systems, hand-held instruments, software, and other devices. Surgical devices refer to the medical devices that are used for various surgical procedures that help in the identification, treatment, and cure of a wide range of medical conditions in gynecology such as colposcopy, loop electrical excision, IUD insertion, dilation and curettage (D&C), ovarian cystectomy, tubal ligation, and others. Major applications are laparoscopy, hysteroscopy, dilation and curettage, colposcopy, and others that are used in clinics, hospitals, diagnostic centers, research institutes, and others. The global gynecological devices market is segmented - 1) By Device: Surgical Devices, Diagnostic Imaging Systems, Hand Held Instruments, Software, Other Devices 2) By Application: Laparoscopy, Hysteroscopy, Dilation and Curettage, Colposcopy, Other Applications 3) By End User: Clinics, Hospitals, Diagnostic Centers, Research Institutes, Others End Users The global gynecological devices market size is expected to grow from $11.45 billion in 2022 to $12.44 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global gynecological devices market size is expected to reach $17.04 billion in 2027 at a CAGR of 8.2%. The increasing prevalence of gynecological disorders is expected to propel the growth of the gynecology devices market going forward. A gynecological disorder is a condition that interferes with the normal function of female reproductive organs such as the breasts and abdominal and pelvic organs. Gynecology devices are used to control the female reproductive system, including pregnancy and childbirth and they are used to perform various medical producers such as colposcopy, loop electrical excision procedure (LEEP), endometrial biopsy, IUD insertion, dilation and curettage (D&C), tubal ligation, ovarian cystectomy, and others. For instance, in March 2023, according to the World Health Organization (WHO) report, a Switzerland-based intergovernmental organization, endometriosis affects around 190 million women and girls of reproductive age worldwide. Additionally, cervical cancer was the fourth most frequent cancer in women worldwide, with 604,000 new cases and 342,000 expected deaths in 2020, accounting for over 90% of new cases and deaths worldwide in low- and middle-income nations. Therefore, the increasing prevalence of gynecological disorders is driving the growth of the gynecological devices market. Major players in the gynecological devices market are Medtronic Plc., CooperSurgical Inc., Richard Wolf GmbH, Hologic Inc., Boston Scientific Corporation, Stryker Corporation, KARL STORZ SE & Co. KG, Ethicon Inc., MedGyn Products Inc., General Electric Company, Fresenius Medical Care AG & Co. KGaA, Gynex Corporation, Bayer AG, Gynemed Medizinprodukte GmbH & Co. KG, Meril Life Sciences Pvt. Ltd., Siemens AG, and Cook Group. Technological advancements are a key trend gaining popularity in the gynecological devices market. Companies operating in the gynecological devices market are adopting new technologies to sustain their position in the market. For instance, in February 2023, Boston Imaging (Samsung), a US-based company operating in medical imaging technology, introduced Hera W10 Elite, an artificial intelligence-enabled women’s health ultrasound system that allows for the visualization of microcirculatory and sluggish blood in 2D and 3D. Hera W10 Elite offers an advanced MV-Flow function as well as a larger organic light-emitting diode (OLED) display, which allows for better characterization of various ultrasound images that are used in obstetrics and gynecology procedures to provide greater diagnosis insight for clinicians. Furthermore, the platform includes a novel transducer that allows endovaginal visualization of the fetal heart and brain. HeartAssist, ViewAssist, and BiometryAssist are enhanced AI aspects of the system. In December 2021, Hologic, Inc, a US-based medical technology company acquired Bolder Surgical for $160 million. Through this acquisition, Hologic Inc aims to strengthen its product portfolio in the laparoscopic segment to gain a competitive advantage in the women’s health market. Bolder Surgical is a US-based company operating in gynecological devices that are used in laparoscopy. North America was the largest region in the gynecological devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global gynecological devices market report forecast period. The regions covered in the global gynecological devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in gynecological devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The gynecological devices market consists of sales of cesarean forceps, cervical dilators, punch forceps, ultrasound (US) devices, computed tomography (CT) devices, magnetic resonance imaging (MRI) devices, contraceptive devices, fluid management systems, endoscopy devices, and endometrial ablation devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The gynecological devices market research report is one of a series of new reports from The Business Research Company that provides gynecological devices market statistics, including gynecological devices industry global market size, regional shares, competitors with a gynecological devices market share, detailed gynecological devices market segments, market trends and opportunities, and any further data you may need to thrive in the gynecological devices industry. The gynecological devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatology lasers refer to light amplification device that is used to stimulate emissions of radiation to treat skin conditions such as birthmarks, scars, and wrinkles. Lasers in dermatology are used to treat many skin diseases, pigmented lesions, skin resurfacing, removal of tattoos, and skin rejuvenation. The main types of dermatology lasers are gas laser machines, semiconductor laser machines, gem laser machines, and other types. A Gas laser machine refers to a laser that creates coherent light by discharging an electric current through a gas and it is used in treating scars, benign growths, and age-related skin conditions in dermatology. Major technologies are dermatology lasers and non-ablative dermatology lasers which are used in various applications such as therapeutic, aesthetic, and other applications in hospitals, skin care clinics, cosmetic surgical centers, and others. The global dermatology lasers market is segmented - 1) By Type: Gas Laser Machine, Semiconductor Laser Machine, Gem Laser Machine, Other Types 2) By Technology: Ablative Dermatology Lasers, Non-Ablative Dermatology Lasers 3) By Application: Therapeutic, Aesthetic, Other Applications 4) By End Users: Hospitals, Skin Care Clinics, Cosmetic Surgical Centres, Other End Users The global dermatology lasers market size is expected to grow from $1.96 billion in 2022 to $2.07 billion in 2023 at a compound annual growth rate (CAGR) of 5.79%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global dermatology lasers market size is expected to reach $2.68 billion in 2027 at a CAGR of 6.65%. The increase in the incidences of skin cancer is expected to propel the growth of the dermatology lasers market going forward. Skin cancer refers to the uncontrolled proliferation of aberrant skin cells that is caused when skin cells are harmed either by tanning beds or frequent U.V. radiation. Dermatology lasers are used to provide high-intensity light that destroys or shrinks pre-skin cancer or skin cancer cells that enables less swelling, less bleeding, and scarring that helps in quicker healing of patients suffering from skin cancer. For instance, in March 2022, according to the report published by the International Agency for Research on Cancer, a France-based cancer agency of the World Health Organization, around 1.5 million skin cancer cases were diagnosed worldwide out of which 325 000 cases were of melanoma globally in the year 2020. Therefore, an increase in the incidences of skin cancer is driving the growth of the dermatology lasers market. Major players in the dermatology lasers market are ALMA LASERS LTD, Lumenis Be Ltd, Cynosure Inc, Quanta System SpA, Candela Corporation, Beijing Sincoheren S&T Development Co Ltd, Koninklijke Philips N.V, Cutera Inc, CryoLife Inc., Canfield Scientific Inc., biolitec ® AG, IPG Photonics Corporation, Miracle Laser & Skin Care, IRIDEX Corporation and Syneron. Technological advancements are a key trend gaining popularity in the dermatology lasers market. Companies operating in the dermatology lasers market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Lutronic Corporation, a US-based medical equipment manufacturing company launched the ‘Derma V Dermatology Platform’ that brings all the significant lasers required by skin specialists daily into a single technology. The Derma V technology consists of a 1064nm laser plus ICD cooling, IntelliTrack, and a 532nm green laser that is used in the treatment of various skin conditions such as skin rejuvenation, pigments, and vascular. Derma V's innovative, contact-based speed sensing technology, IntelliTrack, intelligently detects handpiece movement, delivering precise coverage of the treatment area three times faster than alternative options. Additionally, optimal cryogen-based epidermal protection enables the operator to treat severe vascular lesions with the energy and power required, as well as work quickly and efficiently, while offering comfort without pressure sensitivity or contact gels. In October 2021, Vitruvian Partners LLP, a UK-based investment firm acquired Fotona Holdings for an undisclosed amount. With this acquisition Vitruvian Partners LLP, aims to support Fototna Holdings to expand its business in Asia and the rest of the world with innovative capabilities in the laser market. Fotona Holdings is a Slovenia-based laser manufacturing company that develops laser for various industrial and medical applications. North America was the largest region in the dermatology lasers market in 2022. The regions covered in the global dermatology lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology lasers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The dermatology lasers market includes revenues earned by entities by providing services such as facial rejuvenation, scar treatment, skin cancer, and wound treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The dermatology lasers market consists of sales of pulsed dye dermatology lasers, solid-state dermatology lasers, Ablative lasers, and nonablative lasers to provide dermatology laser treatment services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatology lasers market research report is one of a series of new reports from The Business Research Company that provides dermatology lasers market statistics, including dermatology lasers industry global market size, regional shares, competitors with a dermatology lasers market share, detailed dermatology lasers market segments, market trends and opportunities, and any further data you may need to thrive in the dermatology lasers industry. This dermatology lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Recombinant proteins refer to modified or edited proteins encoded by recombinant DNA, made up of a plasmid in which the gene of an interest target protein is cloned downstream of a promoter region. They are used to make pharmaceuticals, protein-based polymers for drug delivery, antibodies and enzymes for disease treatment, protein scaffolds for tissue engineering, and a variety of other things. The main types of recombinant protein products are antibodies, cytokines, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and others. Antibodies refer to a protein immune system component that travels through the blood, detects foreign objects like bacteria and viruses, and destroys them. They are used in various applications such as drug and discovery development, therapeutics, research, and others. It is used mostly by pharmaceutical and biotechnology companies, academic and research institutes, diagnostic laboratories, and others. The global recombinant proteins market is segmented - 1) By Product: Antibodies, Cytokines, Immune Checkpoint Protein, Virus Antigens, Enzymes, Recombinant Regulatory Proteins, Hormones, Other Products 2) By Application: Drug And Discovery Development, Therapeutics, Research, Other Applications 3) By End Users: Pharmaceutical And Biotechnology Companies, Academic And Research Institute, Diagnostic Laboratories, Other End Users The global recombinant proteins market size is expected to grow from $1.91 billion in 2022 to $2.12 billion in 2023 at a compound annual growth rate (CAGR) of 11.29%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global recombinant proteins market size is expected to reach $3.35 billion in 2027 at a CAGR of 12.10%. A rising number of regulatory approvals is expected to propel the growth of the recombinant protein market going forward. Regulatory approvals refer to any government or health authority authorization for any research involving human subjects. A rising number of regulatory approvals for recombinant proteins is mandatory for all drugs, which includes the treatment of diabetes, and severe chronic diseases like cancer, cardiovascular diseases, endocrine diseases, and viral diseases. For instance, in January 2022, according to the Centre for Drug Evaluation and Research (CDER), a US-based non-profit organization, 38 (76%) of the 50 medications CDER authorized in 2021 received their first U.S. approval. In comparison to 21 of 53 first-in-class pharmaceuticals (39.5%) in 2020, first-in-class drugs made up 27 of the 50 drugs (54%) approved in 2021, the agency observed. The FDA previously reported that 20 drugs were approved (42%), 19 were approved (32%), and 15 were approved (33%). Therefore, the rising number of regulatory approvals is driving the growth of the recombinant protein market going forward. Major players in the recombinant proteins market are Abcam plc, Abnova Corporation, Bio-Rad Laboratories Inc., Merck KGaA, R&D Systems Inc., Proteintech Group Inc., RayBiotech Life Inc., GenScript Biotech Corporation, Elpiscience Biopharmaceuticals Co. Ltd., Elevian Inc., Gigagen Inc., Janssen- Cilag Pvt. Ltd., Abnova Corporation, Sino Biological Inc., OriGene Technologies Inc., Feldan Therapeutics Inc., Randox Laboratories Ltd., Plant Biotechnology Inc. and Infinite Enzymes Inc. Product innovation is the key trend gaining popularity in the recombinant protein market. Major companies operating in the recombinant protein market are focused on developing innovative products to strengthen their position in the market. For instance, in May 2020, Teva and Celltrion Healthcare, a US-based manufacturer of drugs, launched an injection called TRUXIMA, which is a biosimilar to the reference medicine Rituxan®1 (rituximab) on the market for the treatment of rheumatoid arthritis, with a boxed warning for fatal infusion-related complications, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy. The unique feature about this product is its ability to treat various disorders such as Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). In December 2021, Thermo Fisher Scientific Inc., a US-based supplier of scientific instrumentation, reagents, and consumables, acquired PeproTech, Inc. for an undisclosed amount. Through this acquisition, Thermo Fisher Scientific Inc. increases its capabilities for serving high-growth cells and gene therapy. Thermo Fisher's cell culture media products will benefit from PeproTech's recombinant protein portfolio, allowing Thermo Fisher to provide clients with considerable benefits through an integrated offering. PeproTech Inc. is a recombinant protein producer situated in the United States that develops and manufactures recombinant cytokine products for life science research. North America was the largest region in the recombinant protein market in 2022. The regions covered in the global recombinant proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the recombinant protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The recombinant protein market consists of sales of recombinant monoclonal antibodies, interferons, and interleukins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The recombinant proteins market research report is one of a series of new reports from The Business Research Company that provides recombinant proteins market statistics, including recombinant proteins industry global market size, regional shares, competitors with a recombinant proteins market share, detailed recombinant proteins market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant proteins industry. The recombinant proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Single-photon emission computed tomography (SPECT) is a medical imaging technique that uses radioactive tracers and gamma rays to produce 3D images of internal organs and tissues. The tracer can be detected by a gamma camera by emitting gamma rays, allowing for non-invasive and detailed imaging of a patient's internal structure. The main types of single-photon emission computed tomography (SPECT) systems are hybrid and standalone SPECT systems. Hybrid SPECT systems refer to a medical imaging device that combines functional and anatomical information obtained from SPECT and CT or MRI and provides more accurate diagnoses. Various radioisotopes involved in SPECT systems include Tc-99m, Ra-223, Ga-67, I-123, and other radioisotopes in a variety of applications such as oncology, cardiology, neurology, and other applications by hospitals, diagnostic centers, and other end users. The global single-photon emission computed tomography (SPECT) market is segmented - 1) By Type: Hybrid SPECT Systems, Standalone SPECT Systems 2) By Type Of Radioisotopes: Tc-99m, Ra-223, Ga-67, I-123, Other Radioisotopes 3) By Application: Oncology, Cardiology, Neurology, Other Applications 4) By End User: Hospitals, Diagnostic Centers, Other End User The global single-photon emission computed tomography (SPECT) market size is expected to grow from $2.13 billion in 2022 to $2.27 billion in 2023 at a compound annual growth rate (CAGR) of 6.75%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global single-photon emission computed tomography (SPECT) market size is expected to reach $3.04 billion in 2027 at a CAGR of 7.52%. The rise in the prevalence of cases of cancer is expected to propel the growth of the single-photon emission computed tomography (SPECT) market going forward. This rise in the number of cancer cases has resulted from a rise in the aging population, unhealthy lifestyle choices, and environmental factors. Single-photon emission computed tomography (SPECT) helps in the diagnosis, staging, and monitoring of cancer along with other imaging techniques like computed tomography (CT) and Magnetic Resonance Imaging (MRI) scans. For instance, in December 2020, according to a research article published by the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency and part of the World Health Organization, 19.3 million new cancer cases were reported and the number of deaths due to cancer accounted for 10 million in 2020. Female breast cancer is projected to be the most prevalent cancer globally, followed by lung, colorectal, prostate, and stomach cancers. Therefore, the rise in the prevalence of cases of cancer is driving the growth of the single-photon emission computed tomography (SPECT) market. Major players in the single-photon emission computed tomography (SPECT) market are GE HealthCare Technologies Inc., Siemens Healthineers, Bruker Corporation, Digirad Corporation, Mediso Ltd., DDD-Diagnostic A/S, Bracco Diagnostic Imaging, Cardinal Health Inc., Curium Pharma, Spectrum Dynamics Medical, Koninklijke Philips N.V., Beijing Hamamatsu Photon Techniques Inc., Novartis AG, MIE Medical Imaging Electronics GmbH and Global Medical Solutions Private Limited. Technological advancements are a key trend gaining popularity in the single-photon emission computed tomography (SPECT) market. Companies operating in the single-photon emission computed tomography (SPECT) market are adopting new technologies like high-resolution imaging to sustain their position in the market. For instance, in June 2022, Siemens Healthcare, a Germany-based medical device and medical solution manufacturing company, launched the Symbia Pro. Spectra SPECT/CT Scanner. This Symbia Pro. Spectra SPECT/CT device has advanced imaging technology, improved accessibility, optimal low-dose imaging, automated SPECT motion correction, and customized clinical tools designed for imaging in cardiology, oncology, orthopedics, and neurology applications. This device also has the myExam Companion feature, which enables automated workflow guidance. In November 2020, GE Healthcare, a US-based medical technology company, acquired Prismatic Sensors for an undisclosed amount. This acquisition will enable GE Healthcare to use deep silicon detector technology for photon counting computed tomography (PCCT) of prismatic sensors. This advanced technology will enable GE Healthcare to expand its clinical capabilities, achieve detailed visualization of organ structures, and improve tissue characterization. Prismatic Sensors is a Sweden-based start-up company specializing in photon-counting detector manufacturing. North America was the largest region in the single-photon emission computed tomography (SPECT) market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global single-photon emission computed tomography (SPECT) market report during the forecast period. The regions covered in the global single-photon emission computed tomography (SPECT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the single-photon emission computed tomography (SPECT) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The single-photon emission computed tomography (SPECT) market consists of the sale of SPECT/CT and of Single Imaging Gamma Cameras. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The single-photon emission computed tomography (SPECT) market research report is one of a series of new reports from The Business Research Company that provides single-photon emission computed tomography (SPECT) market statistics, including global market size, regional shares, competitors with a single-photon emission computed tomography (SPECT) market share, detailed single-photon emission computed tomography (SPECT) market segments, market trends and opportunities, and any further data you may need to thrive in the single-photon emission computed tomography (SPECT) industry. This single-photon emission computed tomography (SPECT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An infusion pump refers to a medical device that is used to deliver fluids, such as medications or nutrients, into a patient's bloodstream in a controlled manner. Infusion pumps work by using a pump mechanism to control the rate and volume of fluid delivered to the patient. The main product types of infusion pumps are accessories and consumables, and devices. Accessories and consumables refer to additional components that can be used to enhance the performance or functionality of the medical device. The various pump types are volumetric infusion pumps, insulin pumps, enteral infusion pumps, syringe infusion pumps, ambulatory infusion pumps, PCA pumps, and implantable infusion pumps with technologies that include traditional infusion pumps, and specialty infusion pumps. The various applications are chemotherapy or oncology, diabetes management, gastroenterology, pain management or analgesia, pediatrics or neonatology, hematology, and others used in hospitals, ambulatory care settings, specialty clinics, and home care settings. The global infusion pump market is segmented - 1) By Product: Accessories And Consumables, Devices 2) By Type: Volumetric Infusion Pumps, Insulin Pumps, Enteral Infusion Pumps, Syringe Infusion Pumps, Ambulatory Infusion Pumps, PCA Pumps, Implantable Infusion Pumps 3) By Technology: Traditional Infusion Pumps, Specialty Infusion Pumps 4) By Application: Chemotherapy Or Oncology, Diabetes Management, Gastroenterology, Pain Management Or Analgesia, Pediatrics Or Neonatology, Hematology, Other Applications 5) By End Users: Hospitals, Ambulatory Care Settings, Specialty Clinics, Home Care Settings The global infusion pump market size is expected to grow from $12.93 billion in 2022 to $14.01 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global infusion pump market size is expected to reach $19.09 billion in 2027 at a CAGR of 8%. The rise in the prevalence of chronic diseases is expected to propel the growth of the infusion pump market going forward. Chronic diseases refer to noncommunicable diseases (NCDs), which are long-term health conditions and often progress slowly over an extended period. The rise in the prevalence of chronic diseases, such as cancer and diabetes, is mostly driven by changing lifestyles, lack of physical activities, decreasing quality of life, and poor eating habits. Infusion pumps are used to treat some of these chronic diseases by providing accurate dosing, precise fluid delivery, and customized treatments. For instance, in 2020, according to the World Cancer Fund Research International, a UK-based a not-for-profit association related to cancer prevention, there were 18,094,716 million new cases of cancer worldwide. Also, the International Diabetes Federation, an organization of over 230 national diabetes associations in more than 160 countries and territories, projected that, there would be 643 million diabetics worldwide by 2030 and 783 million by 2045. Therefore, a rise in the prevalence of chronic diseases will fuel the infusion pump market growth. Major players in the infusion pump market are Becton Dickinson and Company, Baxter, B Braun SE, ICU Medical, Fresenius Kabi AG, Smiths Medical, Medtronic, Moog Inc., Terumo Corporation, Insulet Corporation, Boston Scientific Corporation, Tandem Diabetes Care Inc., InfuTronix Solutions, Micrel Medical Devices SA, and Shenzhen Mindray Bio-Medical Electronics Co Ltd. Technological advancement has emerged as a key trend gaining popularity in the infusion pump market. Major companies operating in the infusion pump market are focused on developing new technological solutions to strengthen their position. For instance, in November 2022, US-based medical device company Medtronic launched the world's first and only insulin pump infusion set, MiniMed Quick-set Plus. It was uniquely developed with cutting-edge components that aid in lowering insulin preservative loss and maintaining insulin flow and stability to extend an infusion set's wear time by two times. It is the first and only infusion set that is approved by FDA, and it is designed to provide a more convenient and comfortable experience for diabetes patients. In March 2022, a Germany-based lifesaving medicines and technology company, Fresenius Kabi acquired Ivenix Inc for an undisclosed amount. This acquisition will create a comprehensive portfolio for Fresenius Kabi that will constitute the most advanced infusion pump technology, along with infusion supplies and accessories. Ivenix, Inc., is a US-based manufacturer of intravenous drug infusion pump systems. North America was the largest region in the infusion pump market in 2022. The regions covered in the global infusion pump market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the infusion pump market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The infusion pump market consists of sales of large volume infusion pump and elastomeric infusion pump. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The infusion pump market research report is one of a series of new reports from The Business Research Company that provides infusion pump market statistics, including infusion pump industry global market size, regional shares, competitors with a infusion pump market share, detailed infusion pump market segments, market trends and opportunities, and any further data you may need to thrive in the infusion pump industry. This infusion pump market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.